Related Experiment Video

Updated: Apr 19, 2026

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

6.8K

CX-5461 inhibits RNA Pol I in blood cancers

    Cancer Discovery
    |December 6, 2014
    PubMed

    Insights

    The investigational drug CX-5461 shows promise by extending survival in preclinical models of aggressive acute myeloid leukemia and multiple myeloma. This drug targets RNA polymerase I, offering a potential new therapeutic avenue for refractory blood cancers.

    Area of Science:

    • Hematology
    • Oncology
    • Molecular Biology

    Background:

    • Acute myeloid leukemia (AML) and multiple myeloma are aggressive hematologic malignancies.
    • Current therapies often fail in refractory cases, necessitating novel treatment strategies.

    Discussion:

    • The investigational drug CX-5461 targets RNA polymerase I (Pol I), a key regulator of ribosomal DNA transcription.
    • CX-5461 demonstrated efficacy in preclinical models, extending survival in aggressive AML and multiple myeloma.
    • This suggests a potential therapeutic role for Pol I inhibition in hematologic cancers.

    Key Insights:

    • CX-5461 extends survival in preclinical models of aggressive acute myeloid leukemia.
    • CX-5461 extends survival in preclinical models of multiple myeloma refractory to standard therapy.
    • The drug's mechanism involves the inhibition of RNA polymerase I.

    Outlook:

    • Further clinical investigation of CX-5461 is warranted for patients with refractory AML and multiple myeloma.
    • CX-5461 may represent a novel therapeutic strategy targeting Pol I in hematologic malignancies.
    • This research opens avenues for developing targeted therapies against RNA polymerase I in cancer.

    More Related Videos

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

    Published on: May 30, 2025

    1.3K
    Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells09:16

    Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

    Published on: September 1, 2019

    8.2K

    Related Concept Videos

    Transcription Initiation01:47

    Transcription Initiation

    Initiation is the first step of transcription in eukaryotes. Prokaryotic RNA Polymerase (RNAP) can bind to the template DNA and start transcribing. On the other hand, transcription in eukaryotes requires additional proteins, called transcription factors, to first bind to the promoter region in the DNA template. This binding helps recruit the specific RNAP that can assemble on the DNA and start transcription.
    The promoters and enhancers and their accessory proteins allow tight regulation of...
    22.3K
    Eukaryotic RNA Polymerases00:58

    Eukaryotic RNA Polymerases

    RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
    All three eukaryotic RNAPs require specific transcription factors, of which the...
    28.5K
    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    11.7K
    Types of RNA01:20

    Types of RNA

    Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
    RNA Performs Diverse...
    16.8K
    Types of RNA01:23

    Types of RNA

    Overview
    Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
    RNA...
    74.4K
    Inhibitors of Bacterial DNA Synthesis01:28

    Inhibitors of Bacterial DNA Synthesis

    Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
    94